Transaction Overview
Vertex Pharmaceuticals Incorporated disclosed that it will acquire Crinetics Pharmaceuticals, Inc. for a cash consideration of $85.00 per share. The transaction values Crinetics’ equity at approximately $10.0 billion, or about $8.8 billion net of cash that Vertex expects to acquire as part of the deal.
Market Reaction
Following the announcement, Crinetics’ shares surged more than 100%, while Vertex’s stock traded 0.5% lower on the same day.
Approvals and Closing Timeline
The boards of directors of both Vertex and Crinetics approved the transaction unanimously. The parties anticipate closing in the third quarter of 2026, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Crinetics shareholders.
Product Portfolio and Pipeline
Crinetics markets PALSONIFY (paltusotine), the first and only once‑daily oral therapy for adults with acromegaly. PALSONIFY received FDA approval in September 2025 and has subsequently been approved by the European Medicines Agency. Acromegaly affects an estimated 20,000 diagnosed patients in the United States.
The company’s pipeline also includes atumelnant, a once‑daily oral ACTH‑receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia (CAH). Classic CAH has an addressable patient base of roughly 17,000 in the United States. Phase 2 data showed that patients on atumelnant achieved near‑normalization of excess androgen levels while on physiologic glucocorticoid replacement, and the drug was generally well tolerated with no treatment‑related severe or serious adverse events reported to date.
Strategic Rationale and Financial Impact
Reshma Kewalramani, Chief Executive Officer and President of Vertex, described Crinetics as an “excellent strategic fit” because of its focus on serious diseases in specialty markets with significant unmet need and its potential best‑in‑class medicines. Scott Struthers, Founder and CEO of Crinetics, highlighted the partnership’s shared commitment to science and underserved patient communities.
Vertex projects that the combined assets could generate more than $5 billion in annual revenue at peak and expects the acquisition to become accretive to non‑GAAP operating income beginning in 2029.
Financing Structure
Vertex plans to fund the acquisition using a mix of cash on hand and debt. The debt component is supported by a fully committed bridge financing facility of $4.5 billion provided by Bank of America, N.A. and Morgan Stanley Senior Funding, Inc.